From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

NIAID Seeks Biodefense Priority Pathogen Therapeutics

by Global Biodefense Staff
March 6, 2015
MERS Virus Protein Particles

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information regarding efforts to develop therapeutic products that demonstrate activity for the treatment of diseases on the NIAID Category A, B and C Priority Pathogens list.

Candidate products of interest are those with broad spectrum therapeutic activity against viruses or bacterial pathogens and promising anti-toxins as therapeutic products.

Organizations are invited to submit a white paper describing their research efforts to develop any of the following:

  • Products with in vitro and in vivo activity against two or more of the following bacterial pathogens: Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, Rickettsia prowazekii and including urgent, serious and concerning drug-resistant bacterial threats as outlined by the CDC.
  • Products with in vitro and in vivo activity against two or more of the following viral pathogens: Ebola virus, Marburg virus, Variola major, Dengue virus, Chikungunya virus, MERS Coronavirus, and Influenza virus, including activity against discrete strains, species or serotypes within a virus genus.
  • Products with in vitro or in vivo activity against ricin toxin.

The RFI supports the NIAID Division of Microbiology and Infectious Diseases (DMID) in their mission to advance the development of new medical countermeasures against biological agents that are most likely to be used in a terror attack on civilian populations as well as emerging and re-emerging infectious diseases such as MERS, Ebola Virus Disease, antibiotic resistant bacterial infections and pandemic influenza.

Further details are available via Solicitation Number: HHS-NIH-NIAID-BAA-15-037. Responses are due March 13, 2015.

From Our Partners
Tags: AnthraxAntitoxinsBurkholderiaEbolaF. tularensisMERS-CoVMRSARicinY. pestis

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC